Exscientia Initiates Clinical Study to Further Evaluate Functional Precision Medicine Platform in Cancer Patients
07 Février 2024 - 1:00PM
Business Wire
Multicentre EXCYTE-2 study to evaluate
precision medicine platform in patients with acute myeloid
leukaemia
Supports ongoing development of LSD1 inhibitor
(EXS74539) currently in preclinical development
Exscientia plc (Nasdaq: EXAI) today announced the initiation of
EXCYTE-2, an observational clinical study in acute myeloid
leukaemia (AML) to investigate the relationship between ex vivo
drug response (EVDR) measured in primary blood or bone marrow
samples using the company’s deep learning, single-cell precision
medicine platform and actual patient clinical response.
The EXCYTE-2 study will collect blood and bone marrow samples
from first-line patients with AML, with an option to expand to
second-line patients. Both patient groups represent areas of high
unmet medical need with low survival rates. Biobanked tissue
samples, alongside clinical patient data including diagnostic and
outcome data, will be collected from treatment centres with samples
to be processed by Exscientia or partner laboratories. These
partner laboratories will be using Exscientia’s cloud-based AI to
analyse samples remotely.
In addition, the study allows for the evaluation of activity of
EXS74539 (‘539), Exscientia’s LSD1 inhibitor, in a large clinically
annotated sample set. This work has the potential to support the
ongoing development of ‘539, particularly in the selection of
patients for future clinical trials.
The EXCYTE-2 study builds on other previously initiated
precision medicine focused studies, including EXALT-1 and EXCYTE-1.
The EXALT-1 trial was an interventional trial and the first trial
to leverage analysis of drug action in primary human cancer tissues
using high content imaging and deep learning to guide treatment
selection and improve outcomes in patients with late-stage
haematological cancers. EXCYTE-2 will leverage the progress the
company has made on its AI-driven precision medicine platform since
the EXALT-1 trial was completed and will specifically evaluate
earlier stage patient populations. EXCYTE-1 is an ongoing
prospective observational study focused on ovarian cancer.
“This study continues our focus on establishing AI-led ex vivo
drug testing in human tissue samples as the most comprehensive
strategy for preclinical testing of novel therapies, additive to
mouse and other animal models,” said Dr. Nikolaus Krall, EVP of
Precision Medicine at Exscientia. “A robust correlation between our
platform’s results and clinical outcomes has the potential to
change clinical practice for the benefit of AML patients.”
About EXCYTE-2
The EXCYTE-2 trial is a multicentre two-phase study evaluating
the correlation between clinical and ex vivo drug response as
measured using Exscientia’s AI-based precision medicine platform in
AML.
Initially the trial will focus on newly diagnosed AML patients,
with the option to include relapsing/refractory AML patients after
an interim analysis. Blood or bone marrow collected from patients
prior to initiation of therapy will be obtained from biobanks. The
EVDR of commonly used standard of care therapies will then be
evaluated in these patient samples by Exscientia’s AI-based
precision medicine platform. These results will be compared against
patients’ clinical response to treatment, which will be chosen and
evaluated by physicians blinded to the EVDR data. Complete
remission will be used as the primary clinical endpoint and
assessed to monitor association with EVDR. Measurable residual
disease is included as a secondary clinical endpoint.
About Exscientia
Exscientia is an AI-driven precision medicine company committed
to discovering, designing and developing the best possible drugs in
the fastest and most effective manner. Exscientia developed the
first-ever functional precision oncology platform to successfully
guide treatment selection and improve patient outcomes in a
prospective interventional clinical study, as well as to progress
AI-designed small molecules into the clinical setting. Our internal
pipeline is focused on leveraging our precision medicine platform
in oncology, while our partnered pipeline broadens our approach to
other therapeutic areas. By pioneering a new approach to medicine
creation, we believe the best ideas of science can rapidly become
the best medicines for patients. For more information visit us on
www.exscientia.ai or follow us on LinkedIn @ex-scientia and X
@exscientiaAI.
Forward-looking statements
This press release contains forward-looking statements as that
term is defined in the Private Securities Litigation Reform Act of
1995, including with respect to the progress of discovery and
development of candidate molecules. Any statement describing
Exscientia’s goals, plans, expectations, projections, intentions or
beliefs is a forward-looking statement and should be considered an
at-risk statement. Such statements are subject to a number of
risks, uncertainties and assumptions, including those related to
the process of discovering, developing and commercialising product
candidates that are safe and effective for use as human
therapeutics; and the endeavour of building a business around such
product candidates. In light of these risks and uncertainties, and
other risks and uncertainties that are described in the Risk
Factors section and other sections of Exscientia’s Annual Report on
Form 20-F, filed with the Securities and Exchange Commission (SEC)
on March 23, 2023 (File No. 001-40850), and other filings that
Exscientia makes with the SEC from time to time (which are
available at https://www.sec.gov/), the events and circumstances
discussed in such forward-looking statements may not occur, and
Exscientia’s actual results could differ materially and adversely
from those anticipated or implied thereby. Although Exscientia’s
forward-looking statements reflect the good faith judgement of its
management, these statements are based only on facts and factors
currently known by the Company. As a result, you are cautioned not
to rely on these forward-looking statements.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20240207431781/en/
Investor Relations Contact: Sara Sherman / Chinedu Okeke
investors@exscientia.ai Media Contact: Oliver Stohlmann
media@exscientia.ai
Exscientia (NASDAQ:EXAI)
Graphique Historique de l'Action
De Avr 2024 à Mai 2024
Exscientia (NASDAQ:EXAI)
Graphique Historique de l'Action
De Mai 2023 à Mai 2024